Clinical trials: Enterobacteriaceae Infections
Typhoid Fever
Commercial Typhoid Tests Validation
The study aims to perform a head to head comparison of 11 typhoid tests currently in the market and simultaneously develop a sample set that can be used in future evaluations of emerging technologies.
- Trial name
- NCT04673487
- Testing
- 1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test
- Where
- Kenya
- Volunteers
- 2,000 people
- Sponsor
- Kenya Medical Research Institute
Nosocomial Pneumonia, Ventilator Associated Pneumonia
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
Prospective, multicenter observational study to collect Escherichia coli (E. coli) isolates originating from mechanically ventilated intensive care unit (ICU) patients; in order to characterize phenotype and genotype of E.
- Conditions
- Nosocomial Pneumonia, Ventilator Associated Pneumonia, Escherichia Coli Infections, Escherichia Coli Pneumonia
- Trial name
- COLOCOLI (NCT03303937)
- Volunteers
- 289 people
- Sponsor
- Hôpital Louis Mourier
E Coli Infection, ESBL Producing E.Coli
Cefotetan Therapy for Escherichia Coli Infections
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia caused by E. coli.
- Trial name
- NCT07318584
- Testing
- Cefotetan, Carbapenems, Beta Lactam Antibiotics
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Shigellosis
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
Diarrhoea caused by Shigella (shigellosis) is of major public health importance. However, there are no licensed Shigella vaccines in routine use, with several candidates still in various stages of clinical development.
- Trial name
- NCT05959616
- Testing
- Shigella sonnei 53G, Ciprofloxacin 500 mg
- Where
- Kenya
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Ventilator Associated Pneumonia
PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship
Ventilator-associated pneumonia is the leading cause of nosocomial infection in the ICU. Cephalosporinase-producing Enterobacteriaceae have an increasing incidence.
- Trial name
- NCT05486130
- Where
- France
- Volunteers
- 345 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Urinary Tract Infections
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
The present study aims at demonstrating the efficacy of temocillin in the treatment of UTI requiring parenteral therapy due to a confirmed ESBL producing or AmpC hyperproducing Enterobacteriaceae, resistant to quinolones and…
- Trial name
- TEMO-ESBL (NCT02681263)
- Testing
- Temocillin
- Where
- 19 sites in France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Grenoble
Klebsiella Infections
Prognosis of Klebsiella ESBL Sepsis: Role of 2-HYDRoxy-myristate in Endotoxin Structure
Infections constitute a multiple and heterogeneous set of pathologies, and the first cause of mortality worldwide. Among them, sepsis is a more recent nosological entity, including the most severe forms of acute infectious…
- Trial name
- PoKES2_HYDRES (NCT05193045)
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Plague
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
- Trial name
- NCT00246467
- Testing
- Alhydrogel, rF1 and rV protein antigens
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- PharmAthene UK Limited
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in children and infants from various age groups in the Philippines where Typhoid Fever is highly endemic and an efficacious…
- Trial name
- NCT01437267
- Testing
- Vi-CRM197 vaccine, Pneumococcal conjugate vaccine, Vi Polysaccharide (PS) vaccine
- Where
- Philippines
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Novartis
Cancer
Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E
Rapid and rational health-care interventions are of great importance to efficiently combat the emergence of resistant and virulent bacteria. In recent years, spread of ESBL-E on a global level has been observed.
- Trial name
- CLEAR (NCT01931592)
- Testing
- ESBL eradication regimen
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Maria J.G.T. Vehreschild
Plague
Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers
Plague is an infectious disease of animals and humans caused by bacteria, Yersinia pestis. Modern antibiotics are effective against plague, but if an infected person is not treated promptly the disease is likely to cause illness…
- Trial name
- NCT01381744
- Testing
- Flagellin/F1/V
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Shigellosis
Therapeutic Induction of Endogenous Antibiotics
Shigellosis is one of the major causes of morbidity and mortality in many developing countries. The continued emergence of antibiotic resistant strains has complicated the treatment of shigellosis and has increased the cost of…
- Trial name
- NCT00800930
- Testing
- Sodium Butyrate, Saline
- Where
- 2 sites in Bangladesh
- Volunteers
- 80 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Diarrhea, Diarrhea Infectious
A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
This study aims to address the paucity of accurate incidence data of diarrheal diseases associated with Shigella in Zambia and Burkina Faso.
- Trial name
- ShigOraVax (NCT04312906)
- Testing
- no intervention
- Where
- 3 sites in Burkina Faso, Zambia
- Volunteers
- 1,334 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Bacteremia
Empirical Antibiotic and Outcome in Community-onset Bacteremia
Empirical antibiotic and outcome in Community-onset Bacteremia Caused by third generation cephalosporin resistant Enterobacteriaceae
- Trial name
- NCT03765749
- Where
- Thailand
- Volunteers
- 108 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Carbapenemase-Producing Enterobacteriaceae (CPE), Healthcare-Associated Infections (HAIs)
Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection
This multicenter, cluster-randomized crossover trial aims to evaluate the effectiveness and safety of a bundled intervention-including daily chlorhexidine bathing and targeted antimicrobial and proton pump inhibitor (PPI)…
- Trial name
- NCT07039955
- Testing
- Daily Chlorhexidine Bathing, Antimicrobial and PPI Stewardship Program, Standard Bathing
- Where
- 3 sites in South Korea
- Volunteers
- 5,760 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Quinolone Resistance, ESBL
Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species
This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species.
- Conditions
- Quinolone Resistance, ESBL, Klebsiella Species, Infection
- Trial name
- NCT00518661
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Bacteremia
Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
Ceftazidime-avibactam and aztreonam combination (CAZAVI + ATM) presents a potential alternative for the treatment of metallo-beta-lactamase (MBL)-type carbapenemase-producing Enterobacteriaceae (CPE) bacteremia, particularly…
- Trial name
- NCT06419296
- Where
- 16 sites in Argentina
- Volunteers
- 265 people
- Sponsor
- Hospital Italiano de Buenos Aires